| Symbol | KROS |
|---|---|
| Name | KEROS THERAPEUTICS, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | 99 HAYDEN AVENUE,SUITE 120, BUILDING E, LEXINGTON, Massachusetts, 02421, United States |
| Telephone | +1 617 314-6297 |
| Fax | — |
| — | |
| Website | https://www.kerostx.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001664710 |
| Description | Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. The companys protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis. Additional info from NASDAQ: |
New Form 3 - Keros Therapeutics, Inc. <b>Filed:</b> 2026-08-13 <b>AccNo:</b> 0002146784-26-000002 <b>Size:</b> 18 KB
Read more(10% Negative) KEROS THERAPEUTICS, INC. (KROS) Reports Q3 2026 Financial Results
Read more(10% Negative) KEROS THERAPEUTICS, INC. (KROS) Announces Delay in patient Development Timeline Due to Manufacturing Considerations, Safety Review, Efficacy Assessment
Read moreKeros Therapeutics to Receive Development Milestone Payment from Partner Takeda
Read moreBIENAIME JEAN JACQUES 🟢 acquired 1.0K shares of Keros Therapeutics, Inc. (KROS) at $10.61 Transaction Date: Jul 15, 2026 | Filing ID: 000023
Read morePrener Anne 🟢 acquired 28.7K shares (1 derivative) of Keros Therapeutics, Inc. (KROS) at $10.88 Transaction Date: Jul 01, 2026 | Filing ID: 000007
Read moreNew Form 3 - Keros Therapeutics, Inc. <b>Filed:</b> 2026-07-06 <b>AccNo:</b> 0001797917-26-000005 <b>Size:</b> 9 KB
Read more(10% Negative) KEROS THERAPEUTICS, INC. (KROS) Announces Delay in stage Trials for its evolution Due to Manufacturing Considerations
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT07704099 | Safety and Efficacy of KER-065 in Participants With Duchenne Muscular Dystrophy | Phase2 | Duchenne Muscular Dystrophy | Not_Yet_Recruiting | 2026-09-14 | 2029-08-14 | ClinicalTrials.gov |
| NCT05927012 | A Study to Evaluate the Safety and Preliminary Efficacy of a Response-guided Do… | Phase2 | Iron Deficiency Anemia | Withdrawn | 2023-11-30 | 2026-01-04 | ClinicalTrials.gov |
| NCT05975905 | A Study to Investigate the Safety and Efficacy of KER-012 in Combination With B… | Phase2 | Pulmonary Arterial Hypertension | Terminated | 2023-10-17 | 2025-03-11 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| KER-065 | Other | Phase PHASE2 | Duchenne Muscular Dystrophy | NOT_YET_RECRUITING | NCT07704099 |
| KER-065 | Other | Phase PHASE2 | Duchenne Muscular Dystrophy | NOT_YET_RECRUITING | NCT07704099 |
| Placebo for 24 Weeks followed by Dose B KER-012 for 72 weeks | Other | Phase PHASE2 | Pulmonary Arterial Hypertension | TERMINATED | NCT05975905 |
| Dose C KER-012 | Other | Phase PHASE2 | Pulmonary Arterial Hypertension | TERMINATED | NCT05975905 |
| Dose B KER-012 | Other | Phase PHASE2 | Pulmonary Arterial Hypertension | TERMINATED | NCT05975905 |
| Dose A KER-012 | Other | Phase PHASE2 | Pulmonary Arterial Hypertension | TERMINATED | NCT05975905 |
| KER-047 | Other | Phase PHASE2 | Iron Deficiency Anemia | WITHDRAWN | NCT05927012 |
| Placebo for 24 Weeks followed by Dose B KER-012 for 72 weeks | Other | Phase PHASE2 | Pulmonary Arterial Hypertension | COMPLETED | NCT05975905 |
| Dose C KER-012 | Other | Phase PHASE2 | Pulmonary Arterial Hypertension | COMPLETED | NCT05975905 |
| Dose B KER-012 | Other | Phase PHASE2 | Pulmonary Arterial Hypertension | COMPLETED | NCT05975905 |
| Dose A KER-012 | Other | Phase PHASE2 | Pulmonary Arterial Hypertension | COMPLETED | NCT05975905 |
| Placebo for 24 Weeks followed by Dose B KER-012 for 72 weeks | BIOLOGICAL | Phase PHASE2 | Pulmonary Arterial Hypertension | COMPLETED | NCT05975905 |
| Dose C KER-012 | BIOLOGICAL | Phase PHASE2 | Pulmonary Arterial Hypertension | COMPLETED | NCT05975905 |
| Dose B KER-012 | BIOLOGICAL | Phase PHASE2 | Pulmonary Arterial Hypertension | COMPLETED | NCT05975905 |
| Dose A KER-012 | BIOLOGICAL | Phase PHASE2 | Pulmonary Arterial Hypertension | COMPLETED | NCT05975905 |
| KER-047 | DRUG | Phase PHASE2 | Iron Deficiency Anemia | WITHDRAWN | NCT05927012 |